MSD's Von Hippel-Lindau disease treatment Welireg receives approval in Korea

[Newsmp] Welireg (belzutifan) by MSD Korea received approval from the Ministry of Food and Drug Safety on the 23rd.

Welireg has been authorized as a therapy for von Hippel-Lindau (VHL) disease, a condition characterized by the development of multiple tumors, by inhibiting cancer-promoting factor (GIF-2a) associated with angiogenesis, cell proliferation, and tumor growth.

This can help slow down tumor progression and decrease the risk of repetitive tumor resection surgeries in patients with Von Hippel-Lindau disease, where the cancer-inducing factor is not regulated due to mutations in tumor suppressor genes.

The Ministry of Food and Drug Safety explained that Welireg is used in the treatment of non-surgical cases of renal cell carcinoma, central nervous system hemangioblastoma, and pancreatic neuroendocrine tumors in adult patients with von Hippel-Lindau disease.